Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: A two-year study

Menopause

Volumn 7, Issue 6, 2000, Pages 375-382

  Watts, Nelson B ^a,d   Nolan, Joseph C ^b   Brennan, John J ^b   Yang, Hwa Ming ^c   Akin, M ^c   Bachmann, G A ^c   Block, M B ^c   Downs Jr , R ^c   Emkey, R ^c   Fleischmann, R ^c   Genant, H K ^c   Greenwald, M ^c   Khairi, S ^c   Harris, S T ^c   Lenihan Jr , J P ^c   Lucas, J ^c   McIlwain, H ^c   McNaney Flint, H ^c   Melchione, T E ^c   Mortola, J ^c   Notelovitz, M ^c   Rebar, R ^c   Schwartz, S ^c   Scialli, A R ^c   Sevin, B U ^c   Silverman, S ^c   Sperling, M ^c   Speroff, L ^c   Stoltz, R ^c   Trabal, J ^c   Varner, E ^c   Watts, N ^c   Weiss, S ^c   more..

^a EMORY UNIVERSITY   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c Emory Clinic ^*

^d EMORY CLINIC   (United States)

Author keywords

Bone markers; Bone mineral density; Estrogen replacement therapy; Menopause; Osteoporosis; Plasma estrogens

Indexed keywords

CALCIUM CARBONATE; CITRATE CALCIUM; ESTRADIOL; ESTROGEN; GESTAGEN; OSTEOCALCIN; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CORRELATION FUNCTION; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 0033690880     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200011000-00002     Document Type: Article

References (34)

1. Involutional osteoporosis
2. Epidemiology of osteoporosis and osteoporotic fractures
3. Epidemiology of vertebral fractures in women
4. Estrogen replacement therapy I: A 10-year prospective study in the relationship to Osteoporosis
5. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
6. Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females
7. The effects of estrone (Ogen) on spinal bone density of postmenopausal women
8. Effect of estrone sulfate on postmenopausal bone loss
9. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
10. Estrogens in the prevention of osteoporosis in postmenopausal women
11. Estrogens, bone mass, and osteoporotic fractures
12. Prevention and treatment of osteoporosis with hormone replacement therapy
13. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis
14. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study)
15. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: A population-based study
16. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy
17. Biochemical markers of bone turnover I: Theoretical considerations and clinical use in osteoporosis
18. Biochemical markers of bone turnover for the clinical investigation of osteoporosis
19. New developments in biochemical markers for osteoporosis
20. Biochemical markers of bone turnover II: Diagnosis, prophylaxis, and treatment of osteoporosis
21. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study
22. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
23. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
24. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis
25. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion
26. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women
27. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density
28. Minimal levels of serum estradiol prevent postmenopausal bone loss
29. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures
30. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
31. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density
32. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement of calcium supplementation
33. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group
34. Monitoring osteoporosis therapy with bone densitometry